SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares, rose in value on Wednesday, June 18, with the stock price up by 0.64% to the previous day’s close as strong demand from buyers drove the stock to $1.57.
Actively observing the price movement in the last trading, the stock closed the session at $1.56, falling within a range of $1.51 and $1.57. The value of beta (5-year monthly) was 2.274. Referring to stock’s 52-week performance, its high was $2.12, and the low was $0.77. On the whole, SLS has fluctuated by -10.29% over the past month.
With the market capitalization of SELLAS Life Sciences Group Inc currently standing at about $156.65 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLS’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SLS currently trading nearly -5.42% and 2.27% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.75, while the 7-day volatility ratio is showing 2.15% which for the 30-day chart, stands at 5.21%. Furthermore, SELLAS Life Sciences Group Inc (SLS)’s beta value is 2.27, and its average true range (ATR) is 0.13.
A comparison of SELLAS Life Sciences Group Inc (SLS) with its peers suggests the former has fared considerably weaker in the market. SLS showed an intraday change of 0.64% in last session, and over the past year, it grew by 4.67%%.
Data on historical trading for SELLAS Life Sciences Group Inc (NASDAQ:SLS) indicates that the trading volumes over the past 10 days have averaged 2.26 and over the past 3 months, they’ve averaged 2.05 million. According to company’s latest data on outstanding shares, there are 99.78 million shares outstanding.
Nearly 2.11% of SELLAS Life Sciences Group Inc’s shares belong to company insiders and institutional investors own 14.33% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.22 million shares as on 2025-05-30, resulting in a short ratio of 4.15. According to the data, the short interest in SELLAS Life Sciences Group Inc (SLS) stood at 1238.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 7.71 million. The stock has risen by 50.96% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLS stock heading into the next quarter.
